Inpharmus

Brain Tumor Awareness Month highlights a critical reality:

Outcomes in neuro-oncology are shaped not only by scientific progress, but by how timely andeffectively care is delivered.

Molecular classification has become integral to diagnosis, increasing both precision and complexity.At the same time, evidence shows that delays in treatment pathways are associated with worsesurvival outcomes.

The challenge is no longer only what is scientifically possible, but what can be consistently deliveredin clinical practice.

Scientific progress must be matched with operational precision.

Primary Immunodeficiencies are often described as “rare.”

Yet in clinical practice, the real challenge is not rarity alone, but recognition.

Delayed diagnoses, heterogeneous presentations, and fragmented care pathways continue to shape patient outcomes.

Initiatives like World PI Week remind us that awareness is not the endpoint.

It is the starting point for earlier suspicion, more accurate diagnosis, and equitable access to care.

Because in Primary Immunodeficiencies, what remains unseen often defines the patient journey.

We were pleased to welcome our CEO İsmet İnce to Inpharmus Türkiye for our second Country Visit meeting of 2026.

As part of our MERAT strategy, our operations in Türkiye continue to grow in both scale and scope. The energy of our team and their strong ex*****on mindset clearly reflect our Speed & Star culture in action.

We are moving with focus, accelerating with purpose, and building sustainable impact throughout our unicorn journey.